GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (NAS:VYGR) » Definitions » Cyclically Adjusted FCF per Share

Voyager Therapeutics (Voyager Therapeutics) Cyclically Adjusted FCF per Share : $-0.30 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Voyager Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was $0.991. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.30 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-01), Voyager Therapeutics's current stock price is $8.40. Voyager Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $-0.30. Voyager Therapeutics's Cyclically Adjusted Price-to-FCF of today is .

During the past 11 years, the highest Cyclically Adjusted Price-to-FCF of Voyager Therapeutics was 119.78. The lowest was 77.33. And the median was 84.62.


Voyager Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Voyager Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Cyclically Adjusted FCF per Share Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.41

Voyager Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.41 -0.30

Competitive Comparison of Voyager Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Voyager Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.991/131.7762*131.7762
=0.991

Current CPI (Mar. 2024) = 131.7762.

Voyager Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 4.380 99.621 5.794
201506 -0.509 100.684 -0.666
201509 -0.272 100.392 -0.357
201512 -0.388 99.792 -0.512
201603 -0.397 100.470 -0.521
201606 -0.393 101.688 -0.509
201609 -0.421 101.861 -0.545
201612 -0.664 101.863 -0.859
201703 -0.668 102.862 -0.856
201706 -0.648 103.349 -0.826
201709 -0.623 104.136 -0.788
201712 -0.512 104.011 -0.649
201803 1.480 105.290 1.852
201806 -0.745 106.317 -0.923
201809 -0.575 106.507 -0.711
201812 -0.769 105.998 -0.956
201903 3.720 107.251 4.571
201906 -0.886 108.070 -1.080
201909 -0.619 108.329 -0.753
201912 -0.726 108.420 -0.882
202003 -0.820 108.902 -0.992
202006 -0.623 108.767 -0.755
202009 -0.793 109.815 -0.952
202012 -0.685 109.897 -0.821
202103 -0.578 111.754 -0.682
202106 -0.611 114.631 -0.702
202109 -0.566 115.734 -0.644
202112 0.287 117.630 0.322
202203 0.904 121.301 0.982
202206 -0.515 125.017 -0.543
202209 -0.417 125.227 -0.439
202212 -0.342 125.222 -0.360
202303 2.919 127.348 3.021
202306 -0.047 128.729 -0.048
202309 -0.498 129.860 -0.505
202312 -0.486 129.419 -0.495
202403 0.991 131.776 0.991

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Voyager Therapeutics  (NAS:VYGR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 11 years, the highest Cyclically Adjusted Price-to-FCF of Voyager Therapeutics was 119.78. The lowest was 77.33. And the median was 84.62.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Voyager Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (Voyager Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Executives
Todd Alfred Carter officer: Chief Scientific Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Robin Swartz officer: Chief Operating Officer C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandell Jacquelyn Fahey officer: Chief Legal Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Alfred Sandrock director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Robert W. Hesslein officer: Senior VP & General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Jude Onyia director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Neurocrine Biosciences Inc 10 percent owner 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Glenn Pierce director
Michael J Higgins director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140